• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Potential Benefit of Rituximab in Rhupus Patients From a Single-Center: A Series of 16 Cases
Conclusions In rhupus refractory to conventional treatment, T or B lymphocytes targeted therapies, and particularly rituximab, seem to be a relevant therapeutic option unlike anticytokine biologics.
Source: JCR: Journal of Clinical Rheumatology - November 24, 2022 Category: Rheumatology Tags: Concise Report Source Type: research

Intracranial rheumatoid nodule causing recurrent transient neurological deficits
Pract Neurol. 2022 Oct 5:pn-2022-003489. doi: 10.1136/pn-2022-003489. Online ahead of print.ABSTRACTA 67-year-old man with rheumatoid arthritis developed recurrent acute onset of stereotyped focal neurological abnormalities. Cerebral imaging showed a mass lesion in the left parieto-occipital lobe. Imaging did not show the time evolution expected in stroke and so he underwent an extensive workup, which was inconclusive. Brain biopsy identified a rheumatoid nodule causing an extensive inflammatory reaction that mimicked a mass. Following treatment with intravenous corticosteroids and rituximab infusions, his clinical conditi...
Source: Practical Neurology - October 5, 2022 Category: Neurology Authors: Natalie Brossard-Barbosa Laura Donaldson Elena Sokolova Laila AlShafai Edward Margolin Source Type: research

The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis.
CONCLUSION: Abatacept and TNFi were associated with decreased risk of CVD compared to csDMARDs. Minimizing glucocorticoid use and optimizing MTX dose may improve CV outcomes in patients with RA. PMID: 32801134 [PubMed - as supplied by publisher]
Source: Journal of Rheumatology - August 18, 2020 Category: Rheumatology Tags: J Rheumatol Source Type: research

Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
ConclusionsRA TNFi non-responder patients who received second line tocilizumab or abatacept had more benefit on CV events prevention compared with rituximab.
Source: Canadian Journal of Cardiology - January 16, 2020 Category: Cardiology Source Type: research

Risk of Myocardial Infarction and Stroke in Patients With Granulomatosis With Polyangiitis (Wegener's): A Population ‐Based Study
ConclusionPatients with GPA have a significantly increased risk of MI and a non–statistically significant trend toward an increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors are particularly warranted in this patient population, especially early after the diagnosis of GPA.
Source: Arthritis and Rheumatism - September 28, 2016 Category: Rheumatology Authors: J. Antonio Avi ña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Risk of Myocardial Infarction and Stroke in Patients with Granulomatosis with Polyangiitis: A Population‐Based Study
Conclusion: GPA patients have a significantly increased risk of MI, with a non‐statistically significant trend towards increased risk of ischemic stroke. Monitoring for this complication and vigilance in modifying risk factors is particularly warranted in this patient population, especially early after diagnosis. This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatism - May 22, 2016 Category: Rheumatology Authors: J. Antonio Aviña‐Zubieta, Alice Mai, Neda Amiri, Natasha Dehghan, Ju Ann Tan, Eric C. Sayre, Hyon K. Choi Tags: Full Length Source Type: research

Drugs used to treat joint and muscle disease
Publication date: Available online 19 February 2015 Source:Anaesthesia & Intensive Care Medicine Author(s): David G. Lambert Joint disease: Arthritis can be simply broken into osteoarthritis and rheumatoid arthritis (RA). Osteoarthritis is treated with symptomatic pain relief and surgery. RA is a chronic autoimmune disease that causes inflammation of joints (leading to their destruction), tissues around joints and other organ systems. Treatment (for pain) of RA in the first instance is with non-steroidal anti-inflammatory drugs, with second-line treatment using disease-modifying antirheumatic drugs (DMARDs). DMAR...
Source: Anaesthesia and intensive care medicine - February 24, 2015 Category: Anesthesiology Source Type: research